News

More scrutiny, less pay? U.K. docs collected less cash from pharma in 2013

Pharma's payments to doctors are diminishing on both sides of the Atlantic. A new report in Britain finds that drugmakers forked over £38.5 million ($63.9 million) to doctors last year. That's slightly less than the 2012 total of £40 million.

Novartis ousts top Japanese execs amid fresh misconduct allegations

Novartis has cracked down on its Japanese management. The Swiss drugmaker pushed out its top three executives Thursday, after a scathing report from a panel investigating misconduct in a leukemia drug trial.

Sanofi CEO vows to 'go beyond' handouts, hit double-digit growth in Africa

Just days after GlaxoSmithKline announced it would open a new R&D lab and invest more than $200 million in Africa, Sanofi CEO Chris Viehbacher is affirming his country's devotion to Africa, too.

Novartis Japan staffers shredded and deleted to cover trial misconduct, panel finds

Novartis' Japanese unit didn't fake clinical data in a head-to-head leukemia drug study, an investigatory panel found. But that doesn't mean the Swiss drugmaker's staff is off the hook in its latest Japanese scandal. According to the panel's report, employees not only broke the rules repeatedly--they also engaged in a cover-up.

GlaxoSmithKline yanks Paxil batches after FDA warning letter

GlaxoSmithKline has its second recall in as many weeks on its hands, this time affecting batches of the antidepressant Paxil that contain an ingredient manufactured at an Irish plant the FDA says isn't up to snuff.

Can Auxilium's ED hopeful Stendra score with provocative March Madness ads?

Auxilium is marketing Vivus' new erectile dysfunction pill Stendra with a jazzy, suggestive promo video during March Madness, when millions of men are glued to the games.

Amarin triples size of Vascepa sales force with Kowa promo deal

It hasn't been easy being Amarin over the last several months. The Irish drugmaker slammed into one obstacle after another. Read more from FiercePharmaMarketing>>

JAMA: Med-school officials risk conflicts by serving on pharma boards

Much has been made recently over the potential conflicts of interest that arise when doctors take speaking fees from pharma companies. But as a new report suggests, some companies are shelling out a whole lot more to keep medical school and hospital leaders on their boards--where conflicts-of-interest could be much further-reaching.

Industry predicts dire consequences from FDA's generic labeling proposal

The FDA says it wants to level the playing field by having generic drugmakers independently update drug labels when there are known risks to the products. The industry feels as if it is being nudged off a cliff.

ViiV adds pricey new HIV drug Tivicay to patent pool

GlaxoSmithKline CEO Andrew Witty set a precedent back in 2009, when his company placed several patents in a public pool to help developing countries find cures for HIV and other diseases--and then challenged other companies to do the same.

FDA lambastes GSK plant for releasing contaminated products

Much has been made as of late of the manufacturing problems found at some of India's biggest drugmakers. But a warning letter sent in March to a GlaxoSmithKline active pharmaceutical ingredient plant in Cork, Ireland, illustrates that Big Pharma is not immune to quality issues.

Actavis shells out $100M for Thai generics maker in bid for Southeast Asia growth

Actavis has bagged its latest catch. Fresh off last month's deal to buy Forest Laboratories in a $25 billion deal, the generics maker forked over a much smaller amount--$100 million--to buy a small generics company in Thailand.

It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight

Eli Lilly just scored billions in additional sales. A federal judge decreed that an unusual patent on Lilly's cancer drug Alimta is valid. And that means the company keeps its Alimta exclusivity till 2022.

GSK ditches ovarian cancer plans for Votrient

GlaxoSmithKline said Monday that after reviewing data from a Phase III trial, it has withdrawn its application to the European Medicines Agency seeking to expand approval of Votrient to include women with advanced ovarian cancer.

Gilead's Sovaldi triumph puts major hurt on payers' bottom lines

Hepatitis C wonder-drug Sovaldi is still selling at breakneck pace. And at this rate, it could break some insurers. At $84,000 per 12-week treatment course, Sovaldi's quick uptake is threatening payers' earnings, analysts say--and the drug's stellar efficacy profile leaves them with few options.

Supreme Court to hear Teva's Copaxone appeal

The Supreme Court has agreed to hear an appeal of a lower court's decision to invalidate Teva's Copaxone patent, which if restored will shield the drug until September 2015. The decision may, in the least, leave competitors wary of proceeding with generics, giving Teva more time to convert patients to a new, long-acting version of the treatment.

Sanofi taps outcomes exec for new C-level job as 'patient officer'

Last week, Johnson & Johnson chalked up a Big Pharma first by hiring a chief design officer. This week, the groundbreaker is Sanofi. The job? Chief Patient Officer.

Pfizer gets FDA green light for Nexium OTC launch as AZ braces for competition

AstraZeneca has been pulling out all the stops in trying to preserve blockbuster Nexium's revenues for as long as it can. Now, the FDA has approved an over-the-counter version of the drug--but thanks to a 2012 agreement, those sales are on their way to Pfizer.

GSK building up R&D, manufacturing and goodwill in Africa

Lots of drugmakers see Africa as a market that over time can produce some substantial business. But GlaxoSmithKline is not just manufacturing and selling drugs there. It is going one better with a new "open lab" R&D facility to let African researchers work on the drugs needed by Africans for noncommunicable diseases.

Biogen hemophilia nod puts Baxter's to-be-spun-off biopharma unit on notice

Biogen Idec now has FDA approval for Alprolix, the first in a new wave of long-acting hemophilia treatments on their way to market. For Biogen, the thumbs-up is an opportunity to grab market share with a hemophilia B product that works three times as long as current clotting factors. But what will the ensuing market battle mean for Baxter?